Anrotinib and Tirelizumab in First-line Treatment of RM-NPC
NCT05981157
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
27
Enrollment
OTHER
Sponsor class
Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG:
Anrotinib plus Tirelizumab
Sponsor
Zhongshan People's Hospital, Guangdong, China